Kawanishi, Japan

Yoshikazu Oka


Average Co-Inventor Count = 2.5

ph-index = 5

Forward Citations = 69(Granted Patents)


Location History:

  • Kobe, JA (1977 - 1978)
  • Kobe, JP (1979 - 1980)
  • Kawanishi, JP (1984 - 1992)

Company Filing History:


Years Active: 1977-1992

Loading Chart...
10 patents (USPTO):Explore Patents

Title: The Innovative Contributions of Yoshikazu Oka

Introduction

Yoshikazu Oka is a prominent inventor based in Kawanishi, Japan. He has made significant contributions to the field of chemistry, particularly in the development of bicyclic compounds. With a total of 10 patents to his name, Oka's work has had a substantial impact on the pharmaceutical industry.

Latest Patents

Oka's latest patents include a process for the preparation of bicyclic compounds. These new bicyclic compounds, inclusive of salts, have shown inhibitory activities of angiotensin converting enzyme and bradykinin decomposing enzyme. They are recognized for their potential use as antihypertensive agents. The compounds are characterized by a specific formula where R¹ and R² can represent various chemical groups, contributing to their effectiveness in medical applications.

Career Highlights

Throughout his career, Yoshikazu Oka has worked with notable companies such as Takeda Chemical Industries, Inc. and Senju Pharmaceutical Co., Ltd. His experience in these organizations has allowed him to refine his expertise in chemical innovations and patent development.

Collaborations

Oka has collaborated with esteemed colleagues, including Akio Miyake and Kohei Nishikawa. These partnerships have fostered a collaborative environment that has led to groundbreaking advancements in their field.

Conclusion

Yoshikazu Oka's contributions to the field of chemistry and his innovative patents have positioned him as a key figure in the development of antihypertensive agents. His work continues to influence the pharmaceutical industry and improve health outcomes.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…